从Ca~(2+)-CaN-NFAT_3信号通路探讨益心泰对慢性心力衰竭家兔心肌重构的作用
|
摘要
目的：从Ca2+-CaN-NFAT3信号通路探讨益心泰对慢性心力衰竭家兔心肌重构的作用机理。
方法：用阿霉素建立慢性心力衰竭家兔模型,将造模成功的家兔分为模型组、益心泰低、中、高剂量组和氯沙坦钾组；另设正常对照组,共6组。每天上午对家兔进行灌胃,用药组根据成人体表面积换算法,折算后生药量为：益心泰低、中、高剂量组分别按照2.1g/kg、4.2g/kg、8.4g/kg灌胃,氯沙坦钾组按照2.75mg/kg灌胃,模型组和正常组灌服同等体积的生理盐水。1次/d,共用药4周。实验结束后观察血清脑钠肽浓度,心脏超声指标、心肌重构指标以及心肌组织病理结构、心肌超微结构改变；同时从Ca2+-CaN-NFAT3信号通路着手,检测心肌细胞内钙离子浓度,心肌组织CaN的活性,心肌组织NFAT3的蛋白表达及蛋白磷酸化,GATA4及C-Myc的蛋白表达。
结果：用药4周后,(1)与模型组比较,各用药组血清BNP水平明显降低(P<0.01)；与低剂量组比较,益心泰中、高剂量组和氯沙坦钾组血清BNP水平明显降低(P<0.01)；(2)与模型组比较,益心泰中、高剂量组和氯沙坦钾组心脏超声指标LVEF、LVFS和E/A明显升高(P<0.01),IVS、LVPW、LVIDs、LVIDd明显下降(P<0.01)；(3)与模型组比较,益心泰中、高剂量组和氯沙坦钾组心脏指数和左心室重量指数明显降低(P<0.01)；与低剂量组比较,益心泰中、高剂量组和氯沙坦钾组心脏指数和左心室重量指数明显降低(P<0.01)；(4)与模型组比较,各用药组心肌细胞内Ca2+明显减少,心肌组织内CaN含量明显降低(P<0.01)；与低剂量组比较,益心泰中、高剂量组和氯沙坦钾组Ca2+和CaN含量明显降低(P<0.05或P<0.01)；(5)与模型组比较,各用药组心肌组织NFAT3、p-NFAT3、 GATA4、C-Myc表达明显下降(P<0.05或P<0.01)；与低剂量组比较,益心泰中、高剂量组和氯沙坦钾组NFAT3、GATA4、C-Myc表达明显降低(P<0.05或P<0.01)；(6)与模型组比较,益心泰中、高剂量组和氯沙坦钾组心肌组织NFAT3mRNA、GATA4mRNA、 C-Myc mRNA表达明显下降(P<0.01)；与低剂量组比较,益心泰中、高剂量组和氯沙坦钾组NFAT3mRNA、 GATA4mRNA、 C-Myc mRNA表达明显降低(P<0.05或P<0.01)；(7)各用药组心肌细胞损伤与模型组比较均有不同程度的减轻。间质炎细胞浸润较模型组减少,水肿也有所减轻。心肌超微结构也较模型组显著改善。
结论益心泰能抑制Ca2+-CaN-NFAT3信号传导通路,改善心肌重构,从而改善慢性心力衰竭家兔的心功能。且益心泰中、高剂量组疗效明显优于低剂量组。
Objective To investigate the impact and mechanism on the myocardial remodeling of Yi-Xin tai on rabbit with chronic heart failure from Ca2+-CaN-NFAT3signal pathway.
Methods Established the rabbit model of chronic heart model with adriamycin,and divided the successful model of rabbit into five groups: model group, high^middle and low dose of Yi-Xin tai groups and Losartan Potassium group, plus the normal control group,6groups in all.Every morning rabbit were given drug according to body surface area method,the conversion of crude drugs are as follows:the low、middle and high dose of Yi-Xin tai group was respectively given2.1g/(kg·d、4.2g/(kg·d) and8.4g/(kg·d), Losartan Potassium group was given2.75g/(kg·d), besides, the model group and normal group were given equally volume of physiological saline.Every rabbit was given only once a day for4weeksAfter the experiment we observed the serum concentration of brain natriuretic peptide,echocardiographic index, index of myocardial remodeling and the changes of myocardial tissue pathological structure and the myocardial ultrastructure, mearsured the concentration of myocardial intracellular calcium ion, the activity of CaN in myocardial tissue, protein expression of NFAT3and phosphorylated NFAT3in myocardial tissue、protein expression of GATA4and C-Myc.
Results After4weeks,(1)compared with the model group, the serum levels of BNP of the treatment groups were significantly lower (P<0.01); compared with the low dose group, the levels of BNP of the middle、high dose groups of Yi-Xin tai and Losartan Potassium group were significantly lower(P<0.01);(2) compared with the model group, LVEF、LVFS and E/A of medial、high dose groups of Yi-Xin tai and Losartan Potassium group were significantly higher(P<0.01); IVS、 LVPW、LVIDs、 LVIDd were significantly lower (P<0.01);(3)compared with the model group, the cardiac index and left ventricular mass index of medial、high dose groups of Yi-Xin tai and Losartan Potassium group were significantly lower (P<0.01); compared with the low dose group, the cardiac index and left ventricular mass index of the middle、high dose groups of Yi-Xin tai and Losartan Potassium group were significantly lower (P<0.01);(4) compared with the model group, the concentration of myocardial intracellular calcium ion and the activity of CaN in myocardial tissue of the treatment groups were significantly lower(P<0.01);compared with the low dose group, the concentration of myocardial intracellular calcium ion and the the activity of CaN in myocardial tissue of the middle-. high dose groups of Yi-Xin tai and Losartan Potassium group were significantly lower (P<0.05or P<0.01);(5)compared with the model group, the protein expression of NFAT3> P-NFAT3、GATA4and C-Myc in myocardial tissue of the treatment groups were significantly lower (P<0.05or P<0.01); compared with the low dose group, the protein expression of NFAT3-. GATA4and C-Myc in myocardial tissue of the middle, high dose groups of Yi-Xin tai and Losartan Potassium group were significantly lower (P <0.05or P<0.01);(6)compared with the model group, the expression of NFAT3mRNA. GATA4mRNA, C-Myc mRNA of the middle, high dose groups of Yi-Xin tai and Losartan Potassium group were significantly lower (P<0.01); compared with the low dose group, the expression of NFAT3mRNA. GATA4mRNA. C-Myc mRNA of the middle, high dose groups of Yi-Xin tai and Losartan Potassium group were significantly lower (P<0.05or P<0.01)o(7) Compared with the model group, the damage of the myocardial cell of the treatment groups were alleviated; the infiltration of inflammatory cell reducted and ademo lightened.The myocardial ultrastructure was also significantly improved compared with the model group.
Conclusion Yi-Xin tai can inhibit the myocardial remodeling and improve the cardiac function of the rabbit with chronic heart failure through inhibiting the Ca2+-CaN-NFAT3signal pathway.And the curative effect of medial and high dose groups of Yi-Xin tai is better than the low dose group.
方法：用阿霉素建立慢性心力衰竭家兔模型,将造模成功的家兔分为模型组、益心泰低、中、高剂量组和氯沙坦钾组；另设正常对照组,共6组。每天上午对家兔进行灌胃,用药组根据成人体表面积换算法,折算后生药量为：益心泰低、中、高剂量组分别按照2.1g/kg、4.2g/kg、8.4g/kg灌胃,氯沙坦钾组按照2.75mg/kg灌胃,模型组和正常组灌服同等体积的生理盐水。1次/d,共用药4周。实验结束后观察血清脑钠肽浓度,心脏超声指标、心肌重构指标以及心肌组织病理结构、心肌超微结构改变；同时从Ca2+-CaN-NFAT3信号通路着手,检测心肌细胞内钙离子浓度,心肌组织CaN的活性,心肌组织NFAT3的蛋白表达及蛋白磷酸化,GATA4及C-Myc的蛋白表达。
结果：用药4周后,(1)与模型组比较,各用药组血清BNP水平明显降低(P<0.01)；与低剂量组比较,益心泰中、高剂量组和氯沙坦钾组血清BNP水平明显降低(P<0.01)；(2)与模型组比较,益心泰中、高剂量组和氯沙坦钾组心脏超声指标LVEF、LVFS和E/A明显升高(P<0.01),IVS、LVPW、LVIDs、LVIDd明显下降(P<0.01)；(3)与模型组比较,益心泰中、高剂量组和氯沙坦钾组心脏指数和左心室重量指数明显降低(P<0.01)；与低剂量组比较,益心泰中、高剂量组和氯沙坦钾组心脏指数和左心室重量指数明显降低(P<0.01)；(4)与模型组比较,各用药组心肌细胞内Ca2+明显减少,心肌组织内CaN含量明显降低(P<0.01)；与低剂量组比较,益心泰中、高剂量组和氯沙坦钾组Ca2+和CaN含量明显降低(P<0.05或P<0.01)；(5)与模型组比较,各用药组心肌组织NFAT3、p-NFAT3、 GATA4、C-Myc表达明显下降(P<0.05或P<0.01)；与低剂量组比较,益心泰中、高剂量组和氯沙坦钾组NFAT3、GATA4、C-Myc表达明显降低(P<0.05或P<0.01)；(6)与模型组比较,益心泰中、高剂量组和氯沙坦钾组心肌组织NFAT3mRNA、GATA4mRNA、 C-Myc mRNA表达明显下降(P<0.01)；与低剂量组比较,益心泰中、高剂量组和氯沙坦钾组NFAT3mRNA、 GATA4mRNA、 C-Myc mRNA表达明显降低(P<0.05或P<0.01)；(7)各用药组心肌细胞损伤与模型组比较均有不同程度的减轻。间质炎细胞浸润较模型组减少,水肿也有所减轻。心肌超微结构也较模型组显著改善。
结论益心泰能抑制Ca2+-CaN-NFAT3信号传导通路,改善心肌重构,从而改善慢性心力衰竭家兔的心功能。且益心泰中、高剂量组疗效明显优于低剂量组。
Objective To investigate the impact and mechanism on the myocardial remodeling of Yi-Xin tai on rabbit with chronic heart failure from Ca2+-CaN-NFAT3signal pathway.
Methods Established the rabbit model of chronic heart model with adriamycin,and divided the successful model of rabbit into five groups: model group, high^middle and low dose of Yi-Xin tai groups and Losartan Potassium group, plus the normal control group,6groups in all.Every morning rabbit were given drug according to body surface area method,the conversion of crude drugs are as follows:the low、middle and high dose of Yi-Xin tai group was respectively given2.1g/(kg·d、4.2g/(kg·d) and8.4g/(kg·d), Losartan Potassium group was given2.75g/(kg·d), besides, the model group and normal group were given equally volume of physiological saline.Every rabbit was given only once a day for4weeksAfter the experiment we observed the serum concentration of brain natriuretic peptide,echocardiographic index, index of myocardial remodeling and the changes of myocardial tissue pathological structure and the myocardial ultrastructure, mearsured the concentration of myocardial intracellular calcium ion, the activity of CaN in myocardial tissue, protein expression of NFAT3and phosphorylated NFAT3in myocardial tissue、protein expression of GATA4and C-Myc.
Results After4weeks,(1)compared with the model group, the serum levels of BNP of the treatment groups were significantly lower (P<0.01); compared with the low dose group, the levels of BNP of the middle、high dose groups of Yi-Xin tai and Losartan Potassium group were significantly lower(P<0.01);(2) compared with the model group, LVEF、LVFS and E/A of medial、high dose groups of Yi-Xin tai and Losartan Potassium group were significantly higher(P<0.01); IVS、 LVPW、LVIDs、 LVIDd were significantly lower (P<0.01);(3)compared with the model group, the cardiac index and left ventricular mass index of medial、high dose groups of Yi-Xin tai and Losartan Potassium group were significantly lower (P<0.01); compared with the low dose group, the cardiac index and left ventricular mass index of the middle、high dose groups of Yi-Xin tai and Losartan Potassium group were significantly lower (P<0.01);(4) compared with the model group, the concentration of myocardial intracellular calcium ion and the activity of CaN in myocardial tissue of the treatment groups were significantly lower(P<0.01);compared with the low dose group, the concentration of myocardial intracellular calcium ion and the the activity of CaN in myocardial tissue of the middle-. high dose groups of Yi-Xin tai and Losartan Potassium group were significantly lower (P<0.05or P<0.01);(5)compared with the model group, the protein expression of NFAT3> P-NFAT3、GATA4and C-Myc in myocardial tissue of the treatment groups were significantly lower (P<0.05or P<0.01); compared with the low dose group, the protein expression of NFAT3-. GATA4and C-Myc in myocardial tissue of the middle, high dose groups of Yi-Xin tai and Losartan Potassium group were significantly lower (P <0.05or P<0.01);(6)compared with the model group, the expression of NFAT3mRNA. GATA4mRNA, C-Myc mRNA of the middle, high dose groups of Yi-Xin tai and Losartan Potassium group were significantly lower (P<0.01); compared with the low dose group, the expression of NFAT3mRNA. GATA4mRNA. C-Myc mRNA of the middle, high dose groups of Yi-Xin tai and Losartan Potassium group were significantly lower (P<0.05or P<0.01)o(7) Compared with the model group, the damage of the myocardial cell of the treatment groups were alleviated; the infiltration of inflammatory cell reducted and ademo lightened.The myocardial ultrastructure was also significantly improved compared with the model group.
Conclusion Yi-Xin tai can inhibit the myocardial remodeling and improve the cardiac function of the rabbit with chronic heart failure through inhibiting the Ca2+-CaN-NFAT3signal pathway.And the curative effect of medial and high dose groups of Yi-Xin tai is better than the low dose group.
引文
[1]Gaddam KK, Verma A, Thompson M, et al. Hypertension and cardiac failure in its various forms [J].Med Clin North Am,2009,93(3):665-680
[2]Schannwell CM, Hennersdorf MG, Strauer BE. Hypertension and cardiac failure [J].Internist (Berl),2007,48(9):909-920
[3]Amolda L, McGrath BP, Cocks M, et al.Vasoconstrictor Role for Vasopressin in Experimental Heart Failure in the Rabbit [J] J Clin Invest,1986,78 (3):674-679
[4]沈会,李柳骥.心系病症医家临证精华：心力衰竭[M].北京：人民军医出版社,2008：65-67,69-70,101-103
[5]戴雁彦,张立山.水饮与心衰[J].北京中医药大学学报(中医临床版),2007,14(5)：31-32
[6]翁锦龙.黄芪丹参饮对气虚血瘀慢性心力衰竭患者NT-proBNP, CRP水平及心功能的影响[J].中国医药科学,2011,1(22)：17-19
[7]杨志霞,任秀英,杨阳.慢性收缩性心力衰竭与中医气虚血瘀病机相关性研究[J].中西医结合心脑血管病杂志,2011,9(10)：1153-1154
[8]张景岳,杨杰,安洪泽.加味补阳还五汤治疗慢性充血性心力衰竭气虚血瘀证55例临床观察[J].中医药导报,2011,17(1)：17-18
[9]高嵩松,杜久钢,刘媛媛,等.张艳教授对慢性心衰的中医认识与辩治[J].辽宁中医药大学学报,2008,10(10)：10-11
[10]张艳,礼海,王彩玲.浅谈慢性心衰中医病机病名研究[J].辽宁中医杂
志,2011,38(1)：12-13[11]解海宁,张艳,胡晓虹.气虚血瘀水停在慢性心衰实质研究探讨[J].中华中医药学刊,2007,25(12)：2603-2604.
[12]林凯旋,缪灿铭,麦美琪,等.益气活血利水法治疗慢性心力衰竭的临床研究[J].光明中医,2009,24(11)：2132-2133
[13]宫丽虹.益气活血利水法对慢性充血性心力衰竭病人内皮素及脑利钠肽的影响[J].中西医结合心脑血管病杂志,2007,5(7)：615-616
[14]陆青.益气活血利水法在心力衰竭中的应用[J].长春中医药大学学报,2007,23(5)：42-43
[15]李玲,黄云辉.益气活血利水方对慢性心力衰竭BNP水平影响的临床研究[J].中国社区医师,2009,11(20)：166
[16]谢培怡,李晓玲,许琳,等.益气活血利水法对心力衰竭患者脑钠肽及超敏C-反应蛋白的影响[J].中国中西医结合急救杂志,2011,18(5)：280-283
[17]刘会红,万秀英,李红英,等.益气活血利水法治疗慢性充血性心力衰竭148例[J].北京中医药,2011,30(10)：733-736
[18]王兴.益气活血利水方治疗气虚血瘀型慢性心力衰竭60例[J].中国中医药现代教育杂志,2011,9(9)：30-31
[19]陈金水,吴天敏,陈国梁.参芪扶正注射液对心衰大鼠心肌Bcl-2、 Casepase-8 mRNA表达的影响[J].光明中医,2010,25(8)：1370-1372
[20]王晓波,何双双,卢军.六味通心颗粒对腹主动脉狭窄诱导心衰模型大鼠的影响[J].新疆中医药,2011,29(4)：5-7
[21]杨志霞,林谦,马利,等.黄芪多糖丹参酮对慢性心衰大鼠MIF表达的调控作用[J].中国药理学通报,2011,27(9)：1214-1217
[22]马金,张艳.益气活血复方对慢性心衰大鼠心肌重构影响的实验研究[J].时珍国医国药,2011,22(6)：1361-1362
[23]刘淑荣,张晓华,于清华,等.益气活血利水法治疗心力衰竭大鼠的作用机制[J].中国老年学杂志,2011,31(21)：4191-4193
[24]刘育英,陈涛,张继红,等.芪苈山萸心衰方对充血性心力衰竭大鼠左心室重构影响的实验研究[J].湖北中医学院学报,2010,12(3)：7-9
[25]董波,宋婷婷,董天宝,等.益气强心饮对慢性心衰阳性水泛证大鼠心功能及病理改变的影响[J].中西医结合心脑血管病杂志,2010,8(11)：1358-1359
[26]董波,宋婷婷,董天宝,等.益气强心饮对慢性心衰大鼠心肌细胞凋亡及Fas、FasL基因蛋白影响的实验研究[J].中华中医药学刊,2010,28(10)：2075-2077
[27]郭秋红,李昌,周桦.葶苈生脉方对心衰大鼠血管紧张素II和醛固酮的影响[J].时珍国医国药,2010,21(9)：9-10
[28]赵淑明,郭秋红,张志良,等.葶苈生脉方对慢性心衰大鼠血清肿瘤坏死 因子-α、白细胞介素-6及心肌胶原的影响[J].时珍国医国药,2010,21(1)：、153-154
[29]郭秋红,彭雪梅,赵淑明,等.葶苈生脉方对心衰大鼠Angll及其受体信号传导的影响[川.中药新药与临床药理,2010,21(3)：260-262
[30]郭秋红,刘敬颇,赵淑明,等.葶苈生脉方对心衰大鼠RAAS及心肌组织AT1 mRNA表达的影响[J].中华中医药杂志,2010,25(10)：1654-1656
[31]杨冬花,卞震炯,付蓉.益气温阳活血方对慢性心衰大鼠心室重构基因表达谱的影响[J].陕西中医,2009,30(6)：740-742
[32]Xiao-Le Xu, Hui Ji, Shu-Yi Gu, et al. Modification of alterations in cardiac function and sarcoplasmic reticulum by astragaloside IV in myocardial injury in vivo [J].European Pharmacology,2007,568 (3):203
[33]王玉敏,马琰岩,高俊虹,等.黄芪总提物及其有效成分改善阿霉素致心衰的研究[J].中国实验方剂学杂志,2012,18(7)：208-211
[34]张海宁,牛玲,傅鸣郁,等.黄芪注射液对慢性心力衰竭大鼠心肌保护作用的研究.中国实用医药,2012,7(35)：11-12
[35]罗文继,陈旭,郝春华,等.黄芪甲苷衍生物ASId治疗慢性心力衰竭的机制研究[J].中草药,2011,34(6)：416-420
[36]雷李美,黄丽央,陈义鹏,等.丹参酮IIA磺酸钠对慢性心力衰竭患者血浆B型利钠肽的影响[J].中国临床研究,2013,26(8)：781-782
[37]邱雅慧,薛凌,高夏青.丹参多酚酸盐对慢性心力衰竭患者心功能及炎症因子的影响[J].中国实验方剂学杂志,2013,19(7)：321-323
[38]丁虹.丹参酮IIA磺酸钠对冠心病心力衰竭患者心功能及血浆BNP的影响[J].吉林医学,2013,34(31)：6445-6447
[39]范学民,卢小燕.丹参酮IIA磺酸钠对慢性心力衰竭患者冠状动脉血流动力学的影响[J].北方药学,2013,10(9)：65
[40]Paradis P, Dali-youcef N, Paradis FW, et al. Overexpression of angiotemin Ⅱtypel receptors in eardiomyocytes induces cardiac hypertrophy and remodeling [J]. Proc Natl Aead Sci,2000,97 (2):931
[41]王照华,李永胜,杨乐.丹参酮对肥厚心肌组织中钙调神经磷酸酶的影响 [J].中国医药导报,2011,8(29)：18-21
[42]冯俊,李树生.丹参酮Ⅱ A抑制血管紧张素Ⅱ诱导大鼠心肌肥大的机制[J].高血压杂志,2005,13(8)：488-491
[43]冯俊,李树生,梁黔生,等.丹参酮Ⅱ A对心力衰竭大鼠的心肌凋亡及miR-133水平的影响[J].中国中西医结合杂志,2012,32(7)：930-933
[44]武国霞,郭秀芳.黄芪注射液联合丹参注射液治疗老年慢性心力衰竭的疗效观察[J].贵阳中医学院学报,2013,35(2)：110-111
[45]杨志霞,李振彬,林谦,等.黄芪多糖联合丹参酮阻断慢性心衰大鼠NF-κB激活MIF, TNF-a及IL-6表达的研究[J].中华中医药杂志,2012,27(12)：3221-3224
[46]赵光.红花注射液治疗慢性心力衰竭40例[J].实用中医内科杂志,2007,21(10)：68-69
[47]贾蕾.红花注射液治疗老年冠心病心衰108例[J].陕西中医,2010,31(2)：139-140
[48]张静,李庚山,李国草,等.兔阿霉素心衰模型的建立[J].心脏杂志,2004,16(5)：437-439
[49]Singal PK, Panagia V.Direct effects of adriamycin on the rat heart sarcolemma [J].Res commun Chem Pathol Pharmacol,1984,43 (1):67-77
[50]Torii M, Ito H, Suzuki T.Lipid peroxidation and myocardial vulnerability in hypertrophied SHR myocardium [J].Exp Mol Pathol,1992,57(1):29-38
[51]张小丽.大蒜素对阿霉素性心衰大鼠心功能的保护作用及其线粒体机制[J].药学进展,2010,34(1)：30-35
[52]黄先玫,康曼丽.阿霉素对实验兔心功能及心肌细胞内游离钙浓度的影响[J].浙江医学,2000,22(7)：402-404
[53]Polovlkova OG, Makeeva OA, Lezhnev AA, et al.Expression profile of calcineurin pathway genes in myocardium tissues in relation to ischemic heart remodeling in humans [J].Mol Biol (Mosk),2013,47(3):433-440.
[54]Lee TM, Lin MS, Chang NC. Effect of ATP-sensitive potassium channel agonists on ventricular remodeling in healed rat infarcts[J]. Am Coll Cardiol,2008, 51(13):1309-1318.
[55]葛均波,徐永健.内科学[M].北京：人民卫生出版社,2013：166
[56]Polovlkova OG, Makeeva OA, Lezhnev AA, et al.Expression profile of calcineurin pathway genes in myocardium tissues in relation to ischemic heart remodeling in humans [J].Mol Biol (Mosk),2013,47(3):433-440.
[57]Tang M, Li J, Huang W, et al. Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts [J].Cardiovasc Res,2010,88(3):424-433
[58]Sanna B, Brandt E B, Kaiser R A, et al. Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo[J]. Proc Natl Acad Sci USA,2006,103(19):7327-7332.
[59]戴文建,王以光.心肌肥厚分子机制研究进展[J].心血管病学进展,2009,30(1)： 47.
[60]Panther F, Williams T, Ritter O.Inhibition of the calcineurin-NFAT signalling cascade in the treatment of heart failure [J].Recent Pat Cardiovasc Drug Discov, 2009,4(3):180-186.
[61]Wolska B M. Calcineurin and cardiac function:is more or less better for the heart[J]. Am J Physiol Heart Circ Physiol,2009,297(5):1576-1577.
[62]van Rooij E, Doevendans PA, Crijns HJ, et al.MCIPl overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction [J].Cirs Res,2004,94:18-26
[63]Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy[J]. Biochem Biophys Res Commun,2004,322 (4): 1178-1191.
[64]Hu ST, Shen YF, Liu GS, et al.Altered intracellular Ca2+regulation in chronic rat heart failure [J] J Physiol Sci,2010,60(2):85-94
[65]崔国明,东燕,赵勇,等.钙调神经磷酸酶表达与心脏重构的关系[J].中华实用诊断与治疗杂志,2011,25(8)：758-762
[66]Diedriehs H, Hagemeister J, Chi M, et al. Activation of the calcineurin/NFAT signalling cascade starts early in human hypertrophic myocardium [J]. J Int Med Res,2007,35(6):803-818
[67]Lu M, Wang H, Wang J,et al.Astragaloside IV Protects against Cardiac Hypertrophy via Inhibiting the Ca2+/CaN Signaling Pathway[J].Planta Med,2014, 80(1):63-69
[68]Berry JM,Le V, Rotter D,et al.Reversibility of adverse, calcineurin-dependent cardiac remodeling [J].Circ Res,2011,109(4):407-417
[69]Wang GJ, Yao YS, Wang HX, et al.Calcineurin contributed to tumor necrosis factor alpha-induced cardiomyocyte hypertrophy in rats [J].Zhongguo Ying Yong ShengLi Xue Za Zhi,2012,28(2):184-188.
[70]郭炳彦,韩瑞,石英辉,等.姜黄素对血管紧张素Ⅱ诱导新生大鼠心肌细胞肥大的保护作用[J].现代中西医结合杂志,2011,20(2)：147-149
[71]Pan ZW, Zhang Y, Mei DH,et al.Scutellarin exerts its anti-hypertrophic effects via suppressing the Ca2+-mediated calcineurin and CaMKII signaling pathways [J]. Naunyn Schmiedebergs Arch Pharmacol,2010,381(2):137-145.
[72]熊娟,潘勇军,郭桂香,等.川芎嗪对肥大心肌细胞中钙调神经磷酸酶信号转导通路的干预作用[J].医药导报,2009,28(10)：1265-1268
[73]Moey M, Gan XT, Huang CX, et al.Ginseng reverses established cardiomyocyte hypertrophy and postmyocardial infarction-induced hypertrophy and heart failure [J].Circ Heart Fail,2012,5(4):504-514.
[74]Guo J, Gan XT, Haist JV, et al.Ginseng inhibits cardiomyocyte hypertrophy and heart failure via NHE-1 inhibition and attenuation of calcineurin activation [J].Circ Heart Fail,2011,4(1):79-88
[75]王照华,李永胜,杨乐,等.丹参酮对肥大心肌细胞中电生理特征和钙调神经磷酸酶活性的作用[J].现代中西医结合杂志,2011,20(32)：4060-4063
[76]童妍,党万太,苗维娜.参附汤对心阳虚型慢性心力衰竭钙调神经磷酸酶-活化T细胞核因子3信号转导通路的影响[J].中国实验方剂学杂志,2012,18(8)： 199-201
[77]党万太,苗维娜,杨晓放,等.基于钙调磷酸酶-活化T细胞核因子3信 号转导通路探究四逆汤治疗心力衰竭的分子机制[J].中国实验方剂学杂志,2011,17(22)：201-204
[78]郭志华,李雅,毛以林,等.益心泰治疗慢性心力衰竭60例临床观察[J].中成药,2008,30(3)：323-325
[79]郭志华,范红辉,李雅,等.益心泰治疗气虚血瘀水停型慢性心力衰竭[J].中西医结合心脑血管病杂志,2009,7(1)：5-6
[80]Meng R, Pei Z, Zhang A, et al. AMPK activation enhances PPARalpha activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway [J] Arch Biochem Biophys,2011,511 (1-2):1-7
[81]Meng RS, Pei ZH, Yin R, et al. Adenosine monophosphate-activated protein kinase inhibits cardiac hypertrophy through reactivating peroxisome proliferator-activated receptor-alpha signaling pathway[J]. Eur J Pharmacol,2009, 620 (1-3):63-70.
[82]Shi J, Zhang YW, Yang Y, et al.ROCKl plays an essential role in the transition from cardiac hypertrophy to failure in mice [J] J Mol Cell Cardiol,2010, 49(5):819-828.
[1]Gaddam KK, Verma A, Thompson M, et al. Hypertension and cardiac failure in its various forms [J].Med Clin North Am,2009,93(3):665-680
[2]Schannwell CM, Hennersdorf MG, Strauer BE. Hypertension and cardiac failure [J].Internist (Berl),2007,48(9):909-920
[3]Bamani GV,Uber PA, Mehra MR.Chronic heart failure:contemporary diagaosis and management[J].Mayo Clin Prec,2010,85(2):180-195.
[4]颜德馨.跟名师学临床系列丛书：颜德馨[M].第2版.北京：中国医药科技出版社,2010：3-4.
[5]杨宝元,任秀英,杨阳,等.慢性收缩性心力衰竭与中医气虚血瘀病机相关性研究[J].中西医结合心脑血管病杂志,2011,9(10)：1153-1154
[6]姜平,李冰,刘艳,等.益气养阴和化瘀利水中药治疗糖尿病合并冠心病慢性心功不全老年患者32例[J].中国中西医结合急救杂志,2011,18(3)：178.
[7]谢兴辉.温阳益气活血利水法配常规西药治疗慢性心力衰竭75例[J].陕西中医,2009,30(6)：646
[8]林凯旋,缪灿铭,麦美琪,等.益气活血利水法治疗慢性心力衰竭的临床研究[J].光明中医,2009,24(11)：2132-2133
[9]郭志华,范红辉,李雅,等.益心泰治疗气虚血瘀水停型慢性心力衰竭[J].中西医结合心脑血管病杂志,2009,7(1)：5-6
[10]刘会红,万秀英,李红英,等.益气活血利水法治疗慢性充血性心力衰竭148例[J].北京中医药,2011,30(10)：733-736
[11]王兴.益气活血利水方治疗气虚血瘀型慢性心力衰竭60例[J].中国中医药现代远程教育,2011,9(9)：30-31
[12]陈英全,谢绍洽.苯那普利对慢性心衰患者心功能-内分泌-细胞因子的影响[J].中国现代医药杂志,2010,12(5)：26-29
[13]伍鹏龙,魏盟,朱伟.Scrf信号通路及在心力衰竭病理生理中的作用[J]国际心血管病杂志,2013,40(1)：6-8,15
[14]朱德胜,冯耀光.心力衰竭时神经内分泌改变[J].中国现代医生,2010,32(10)：130-131.
[15]郎中云,方显明.安心颗粒对慢性心衰大鼠细胞因子和心肌重构的影响[J].时珍国医国药,2011,22(7)：1584-1585
[16]方显明,刘神州,吴功恩,等.安心颗粒对心力衰竭大鼠JAK1-STAT3信号通路的影响.新中医,2011,43(7)：126-129
[17]李莹,马会军.慢性心力衰竭患者血尿酸与心功能的关系[J].当代医学, 2013,19(25) ：41
[18]温继梨,崔晓迎,陈凤英.N端脑钠肽、脑钠肽及ST2与心力衰竭患者严重程度相关性分析[J].中国医药导报,2013,10(2)：76-77,80
[19]谭海彦,朱莉,周萍,等.谈益气活血法对慢性心衰的临床观察及对NT— proBNP的影响[J].求医问药,2011,9(10)：300-301
[20]徐辉.温阳益气行瘀利水对慢性心衰LVEF及血脑利钠肽影响[J].中医临床研究,2011,3(15)：5-7
[21]林凯旋,陈翊.益气活血法改善心衰患者左室射血分数及脑钠肽的临床研究[J].光明中医,2010,25(9)：1614-1615
[22]李玲,黄云辉.益气活血利水方对慢性心力衰竭BNP水平影响的临床研究[J].中国社区医师,2009,11(20)：166
[23]刘茜,周华,戎靖枫.温补肾阳方对心肌梗死后心力衰竭大鼠血流动力学及血清肌钙蛋白Ⅰ和脑钠肽含量的影响[J].天津中医药,2013,30(3)：164-167
[24]王建湘,谭元生,邓满霞.温阳益气、活血利水法对冠脉结扎心肌梗死后心衰大鼠NT-proBNP(?)影响[J].中西医结合心脑血管病杂志,2012,10(3)：325-326
[25]Akkus MN, Polat G, Yurtdas M, et al. Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission[J]. Int Heart J,2009, 50(1):33-45
[26]Fichtlscherer S, RosenbererG, Dirk H, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease[J]. Circulation,2000,102:1000-1006.
[27]刘芳.NT-proBNP, HCY, hs-CRP检测对慢性心衰的诊断价值[J].中国实用医药,2013,8(28)：105-106
[28]翁锦龙.黄芪丹参饮对气虚血瘀慢性心力衰竭患者NT-proBNP. CRP水平及心功能的影响[J].中国医药科学,2011,1(22)：17-19
[29]谢培怡,李晓玲,许琳,等.益气活血利水法对心力衰竭患者脑钠肽及超敏C-反应蛋白的影响[J].中国中西医结合急救杂志,2011,18(5)：280-283
[30]Cowburn PJ,Cleland JGF. Endothelin antagonists for chronic heart failure:do they have a role[J]? Eur Heart J,2001,22 (19):1772-1784
[31]Ohmae M.Endothelin-1 levels in chronic congestive heart failure[J].Wien Klin Wochenschr,2011,123(23-24):714-717
[32]Wang L, Shi J, Zhang Y.Influences of simvastatin on vascular endothelial function of patients with coronary heart disease complicated with congestive heart failure[J].Eur Rev Med Pharmacol Sci,2013,17(12):1590-1593.
[33]Hurli mann D, Enseleit F,Noll G, et al. Endothelin antagonists and heart failure[J]. Curr Hypertens Reports,2002,4 (1):85-92.
[34]McMurray JJV.Heart failure in 10 years time:Focus on pharmacological treatment[J].Heart,2002,88(supp 1Ⅱ):1402-1146
[35]黄平东,罗懿明,刘煜德,等.益气温阳活血利水药对心梗后心衰ET-1、TNF-A. AngⅡ的影响[J].四川中医,2009,27(11)：37-40
[36]王东,刘江,王晓峰.芪红汤治疗慢性心力衰竭气虚血瘀型疗效及对血浆内皮素、脑钠肽的影响[J].新疆医科大学学报,2011,34(4)：379-382
[37]Nishilkimi T, Maeda N, Mmsuoka H. The role of natriuretic peptides in cardioprotection[J]. Cardiovasc Res,2006,69(2):318-328
[38]De Bold AJ, De Bold ML. Determinants of natriuretic peptide production by the heart:basic and clinical implication[J]. Investig Med,2005,53(7):371-377
[39]Tsuneyoshi H, Nishina T, Nomoto T, et al. Atrial natriuretic peptide helps prevent late remodeling after left ventriclar aneurysmrepair[J]. Circulation,2004, 110(11Supp11):174-179
[40]亢顺阳,田大利.血浆心钠素和脑钠素在慢些心力衰竭患者中的水平改变意义分析[J].中国现代药物应用,2013,7(21)：47-48
[41]王永霞,任红杰,朱明军,等.参附益心颗粒对慢性心力衰竭大鼠血清心钠素、脑钠素的影响[J].中国实验方剂学杂志,2011,17(4)：118-120
[42]Xu J, Lu XW, Huang Y, et al. Synergism of simvastatin with losartan prevents angiotensin Ⅱ-induced cardiomyocyte apoptosisin vitro[J].J Pharm Pharmacol, 2009,61 (4):503
[43]Alves AJ, Eynon N, Oliveira J,et al. RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications[J].World J Cardiol,2010,2(7): 187-197.
[44]刘淑荣,张晓华,于清华,等.益气活血利水法治疗心力衰竭大鼠的作用机制[J].中国老年性杂志,2011,31(21)：4191-4193
[45]宫广舵,陈远平,李瑜欣,等.养心通脉颗粒II方对气虚血瘀型心衰大鼠血清AngⅡ, IL-6, TNF-a水平的影响[J].广西中医学院学报,2010,13(4)：1-3
[46]Wang GJ, Wang HX, Yao YS, et al.The role of Ca2+/calmodulin-dependent protein kinase Ⅱ and calcineurin in TNF-a-induced myocardial hypertrophy[J].Braz J Med Biol Res,2012,45(11):1045-1051.
[47]Wang GJ, Yao YS, Wang HX, et al.Calcineurin contributed to tumor necrosis factor alpha-induced cardiomyocyte hypertrophy in rats[J].Zhongguo Ying Yong Sheng Li Xue Za Zhi,2012,28(2):184-188.
[48]Amir O, Rogowski O, David M, et al.Circulating interleukin-10:association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha[J]. Isr Med Assoc J,2010,12(3):158-162
[49]Sven W, Micheala S, Kerstin S, et al. Interleukin-6 induced oxidative stress and endothelial dysfunction by overexpression of the angiotensin 2 type 1 receptor[J]. Cir
Res,2004,94:534-541. [50] Christian M,Kirsten LK, Andreas C, et al. Inflammation and long term mortality in acute congestive heart failure[J]. Am Heart J,2006,151(4):845-850.
[51]Kinugawa T, Kato M, Yamamoto K, et al.Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure[J].Int Heart J.2012,53(3):182-186
[52]赵淑明,郭秋红,张志良,等.葶苈生脉方对慢性心衰大鼠血清肿瘤坏死因子-、白细胞介素-6及心肌胶原的影响[J].时珍国医国药,2010,21(1)：153α-154
[53]王扬,杜立建,陈希芬.益气活血汤对慢性充血性心力衰竭患者抗炎细胞因子及心功能的影响[J].河北中医,2009,31(9)：1292-1294
[54]礼海,张艳,马金.益气活血复方联合运动疗法对慢性心衰大鼠心肌组织 MMP-1及Ⅲ型胶原表达的影响[J].中国中西医结合杂志,2011,31(7)：955-960
[55]黄东平,刘煜德,黄衍寿.益气温阳活血利水药对心梗后心衰大鼠基质金属蛋白酶及心室重塑的影响[J].中药新药与临床药理,2010,21(6)：608-611
[56]马金,张艳.益气活血复方对慢性心衰大鼠心肌重构影响的实验研究[J].时珍国医国药,2011,22(6)：1361-1362
[57]Moshal KS, Rodriguez WE, Sen U, et al. Targeted deletion of MMMP-9 attenuates myocardial contractile dysfunction in heart failure[J]. Physiol Res,2008, 57(3):379-384
[58]刘晓蕾,张艳,礼海.益气活血中药对心力衰竭大鼠MMP-K TIMP-1影响的实验研究[J].天津中医药,2011,28(6)：503-505
[59]Polovlkova OG, Makeeva OA, Lezhnev AA, et al.Expression profile of calcineurin pathway genes in myocardium tissues in relation to ischemic heart remodeling in humans[J].Mol Biol (Mosk),2013,47(3):433-440.
[60]Tang M, Li J, Huang W, et al. Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts[J].Cardiovasc Res,2010,88(3):424-433
[61]Panther F, Williams T, Ritter O. Inhibition of the calcineurin-NFAT3 signalling cascade in the treatment of heart failure [J]. Recent Pat Cardiovasc Drug Discov, 2009,4(3):180-186.
[62]Lu M, Wang H, Wang J,et al.Astragaloside IV Protects against Cardiac Hypertrophy via Inhibiting the Ca2+/CaN Signaling Pathway[J].Planta Med,2014, 80(1):63-69
[63]Wilkins BJ,Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy[J]. Biochem Biophys Res Commun,2004,322 (4):1178-1191.
[64]杨冬花,卞震炯,付蓉.益气温阳活血方对慢性心衰大鼠心室重构基因表达谱的影响[J].陕西中医,2009,30(6)：740-742
[65]郭志华,吴刚强,申思,等.益心泰对慢性心力衰竭大鼠心肌重构钙调神经磷酸酶信号通道的影响[J].中国中医急症杂志,2013,22(1)：17-19
[66]朱茜,贾如意,高佩增.冠心病心力衰竭患者血清NF-κB水平变化及 意义[J].山东医药,2010,50(23)：7-9
[67]Sudhiranjan Gupta,David Young, Ratan, et al. Prevention of Cardiac Hypertrophy and Heart Failure by Silencing of NF-κB[J]. J M01 Biol,2008,375(3): 637
[68]杨志霞,林谦,农一兵,等.黄芪多糖联合丹参酮对心衰大鼠心肌NF-κB通路过度激活的影响[J].北京中医药大学学报,2011,34(9)：609-612
[69]柯元南.心力衰竭的血流动力学[J].中国前沿医学杂志,2010,2(1)：13-15
[70]Chung I, Choudhury A, Lip GY. Platelet activation in acute, decompensated congestive heart failure [J]. Thromb Res,2007,120(5):709-713.
[71]Kandis H, Ozhan H, Ordu S, et al. The prognostic value of mean platelet volume in decompensated heart failure [J]. Emerg Med J,2011,28(7):575-578.
[72]Chung I, Choudhury A, Patel J, et al. Soluble, platelet-bound, and total p-selectin as indices of platelet activation in congestive heart failure[J].Ann Med,2009,41(1): 45-51.
[73]沈荣春,王峰,徐耀忠,等.4项血小板参数检测在慢性心力衰竭诊疗中临床价值[J].交通医学,2013,27(3)：263-265
[74]王中全,张洋, 陈曦,等.hs-CRP和血小板参数与心衰患者病情严重程度的关系[J].中国老年学杂志,2013,33(14)：3320-3322
[75]沈淑静,冼绍,黄衍寿,等.益气温阳活血利水中药对心力衰竭兔的血流动力学影响和配伍研究[J].中国实验方剂学杂志,2013,19(5)：195-199
[76]张艳,海丽,宋婷婷,等.益气活血复方对慢性心衰大鼠血小板活化影响的实验研究[J].世界中西医结合杂志,2008,3(4)：198-200
[77]李华.中药抗心衰合剂治疗气虚血瘀阳虚水泛型充血性心力衰竭临床研究[J].中医中药,2012,9(3)：104-105
[78]刘强,李萌,钟志国,等.益气活血利水汤治疗冠心病慢些心力衰竭44例[J].山东中医杂志,2009,28(8)：533-534
[79]安冬青,王晓峰,陈继红,等.芪红颗粒结合康复治疗气虚血瘀型心力衰竭的临床观察.第十次中国中西医结合学会心血管病暨第五次江西省中西医结合学
会心血管病学术大会论文集：243-246
[80]郑军,刘金玲.中西医结合治疗气虚血瘀型慢性充血性心力衰竭37例[J].西部中医药,2011,24(12)：62-64
[2]Schannwell CM, Hennersdorf MG, Strauer BE. Hypertension and cardiac failure [J].Internist (Berl),2007,48(9):909-920
[3]Amolda L, McGrath BP, Cocks M, et al.Vasoconstrictor Role for Vasopressin in Experimental Heart Failure in the Rabbit [J] J Clin Invest,1986,78 (3):674-679
[4]沈会,李柳骥.心系病症医家临证精华：心力衰竭[M].北京：人民军医出版社,2008：65-67,69-70,101-103
[5]戴雁彦,张立山.水饮与心衰[J].北京中医药大学学报(中医临床版),2007,14(5)：31-32
[6]翁锦龙.黄芪丹参饮对气虚血瘀慢性心力衰竭患者NT-proBNP, CRP水平及心功能的影响[J].中国医药科学,2011,1(22)：17-19
[7]杨志霞,任秀英,杨阳.慢性收缩性心力衰竭与中医气虚血瘀病机相关性研究[J].中西医结合心脑血管病杂志,2011,9(10)：1153-1154
[8]张景岳,杨杰,安洪泽.加味补阳还五汤治疗慢性充血性心力衰竭气虚血瘀证55例临床观察[J].中医药导报,2011,17(1)：17-18
[9]高嵩松,杜久钢,刘媛媛,等.张艳教授对慢性心衰的中医认识与辩治[J].辽宁中医药大学学报,2008,10(10)：10-11
[10]张艳,礼海,王彩玲.浅谈慢性心衰中医病机病名研究[J].辽宁中医杂
志,2011,38(1)：12-13[11]解海宁,张艳,胡晓虹.气虚血瘀水停在慢性心衰实质研究探讨[J].中华中医药学刊,2007,25(12)：2603-2604.
[12]林凯旋,缪灿铭,麦美琪,等.益气活血利水法治疗慢性心力衰竭的临床研究[J].光明中医,2009,24(11)：2132-2133
[13]宫丽虹.益气活血利水法对慢性充血性心力衰竭病人内皮素及脑利钠肽的影响[J].中西医结合心脑血管病杂志,2007,5(7)：615-616
[14]陆青.益气活血利水法在心力衰竭中的应用[J].长春中医药大学学报,2007,23(5)：42-43
[15]李玲,黄云辉.益气活血利水方对慢性心力衰竭BNP水平影响的临床研究[J].中国社区医师,2009,11(20)：166
[16]谢培怡,李晓玲,许琳,等.益气活血利水法对心力衰竭患者脑钠肽及超敏C-反应蛋白的影响[J].中国中西医结合急救杂志,2011,18(5)：280-283
[17]刘会红,万秀英,李红英,等.益气活血利水法治疗慢性充血性心力衰竭148例[J].北京中医药,2011,30(10)：733-736
[18]王兴.益气活血利水方治疗气虚血瘀型慢性心力衰竭60例[J].中国中医药现代教育杂志,2011,9(9)：30-31
[19]陈金水,吴天敏,陈国梁.参芪扶正注射液对心衰大鼠心肌Bcl-2、 Casepase-8 mRNA表达的影响[J].光明中医,2010,25(8)：1370-1372
[20]王晓波,何双双,卢军.六味通心颗粒对腹主动脉狭窄诱导心衰模型大鼠的影响[J].新疆中医药,2011,29(4)：5-7
[21]杨志霞,林谦,马利,等.黄芪多糖丹参酮对慢性心衰大鼠MIF表达的调控作用[J].中国药理学通报,2011,27(9)：1214-1217
[22]马金,张艳.益气活血复方对慢性心衰大鼠心肌重构影响的实验研究[J].时珍国医国药,2011,22(6)：1361-1362
[23]刘淑荣,张晓华,于清华,等.益气活血利水法治疗心力衰竭大鼠的作用机制[J].中国老年学杂志,2011,31(21)：4191-4193
[24]刘育英,陈涛,张继红,等.芪苈山萸心衰方对充血性心力衰竭大鼠左心室重构影响的实验研究[J].湖北中医学院学报,2010,12(3)：7-9
[25]董波,宋婷婷,董天宝,等.益气强心饮对慢性心衰阳性水泛证大鼠心功能及病理改变的影响[J].中西医结合心脑血管病杂志,2010,8(11)：1358-1359
[26]董波,宋婷婷,董天宝,等.益气强心饮对慢性心衰大鼠心肌细胞凋亡及Fas、FasL基因蛋白影响的实验研究[J].中华中医药学刊,2010,28(10)：2075-2077
[27]郭秋红,李昌,周桦.葶苈生脉方对心衰大鼠血管紧张素II和醛固酮的影响[J].时珍国医国药,2010,21(9)：9-10
[28]赵淑明,郭秋红,张志良,等.葶苈生脉方对慢性心衰大鼠血清肿瘤坏死 因子-α、白细胞介素-6及心肌胶原的影响[J].时珍国医国药,2010,21(1)：、153-154
[29]郭秋红,彭雪梅,赵淑明,等.葶苈生脉方对心衰大鼠Angll及其受体信号传导的影响[川.中药新药与临床药理,2010,21(3)：260-262
[30]郭秋红,刘敬颇,赵淑明,等.葶苈生脉方对心衰大鼠RAAS及心肌组织AT1 mRNA表达的影响[J].中华中医药杂志,2010,25(10)：1654-1656
[31]杨冬花,卞震炯,付蓉.益气温阳活血方对慢性心衰大鼠心室重构基因表达谱的影响[J].陕西中医,2009,30(6)：740-742
[32]Xiao-Le Xu, Hui Ji, Shu-Yi Gu, et al. Modification of alterations in cardiac function and sarcoplasmic reticulum by astragaloside IV in myocardial injury in vivo [J].European Pharmacology,2007,568 (3):203
[33]王玉敏,马琰岩,高俊虹,等.黄芪总提物及其有效成分改善阿霉素致心衰的研究[J].中国实验方剂学杂志,2012,18(7)：208-211
[34]张海宁,牛玲,傅鸣郁,等.黄芪注射液对慢性心力衰竭大鼠心肌保护作用的研究.中国实用医药,2012,7(35)：11-12
[35]罗文继,陈旭,郝春华,等.黄芪甲苷衍生物ASId治疗慢性心力衰竭的机制研究[J].中草药,2011,34(6)：416-420
[36]雷李美,黄丽央,陈义鹏,等.丹参酮IIA磺酸钠对慢性心力衰竭患者血浆B型利钠肽的影响[J].中国临床研究,2013,26(8)：781-782
[37]邱雅慧,薛凌,高夏青.丹参多酚酸盐对慢性心力衰竭患者心功能及炎症因子的影响[J].中国实验方剂学杂志,2013,19(7)：321-323
[38]丁虹.丹参酮IIA磺酸钠对冠心病心力衰竭患者心功能及血浆BNP的影响[J].吉林医学,2013,34(31)：6445-6447
[39]范学民,卢小燕.丹参酮IIA磺酸钠对慢性心力衰竭患者冠状动脉血流动力学的影响[J].北方药学,2013,10(9)：65
[40]Paradis P, Dali-youcef N, Paradis FW, et al. Overexpression of angiotemin Ⅱtypel receptors in eardiomyocytes induces cardiac hypertrophy and remodeling [J]. Proc Natl Aead Sci,2000,97 (2):931
[41]王照华,李永胜,杨乐.丹参酮对肥厚心肌组织中钙调神经磷酸酶的影响 [J].中国医药导报,2011,8(29)：18-21
[42]冯俊,李树生.丹参酮Ⅱ A抑制血管紧张素Ⅱ诱导大鼠心肌肥大的机制[J].高血压杂志,2005,13(8)：488-491
[43]冯俊,李树生,梁黔生,等.丹参酮Ⅱ A对心力衰竭大鼠的心肌凋亡及miR-133水平的影响[J].中国中西医结合杂志,2012,32(7)：930-933
[44]武国霞,郭秀芳.黄芪注射液联合丹参注射液治疗老年慢性心力衰竭的疗效观察[J].贵阳中医学院学报,2013,35(2)：110-111
[45]杨志霞,李振彬,林谦,等.黄芪多糖联合丹参酮阻断慢性心衰大鼠NF-κB激活MIF, TNF-a及IL-6表达的研究[J].中华中医药杂志,2012,27(12)：3221-3224
[46]赵光.红花注射液治疗慢性心力衰竭40例[J].实用中医内科杂志,2007,21(10)：68-69
[47]贾蕾.红花注射液治疗老年冠心病心衰108例[J].陕西中医,2010,31(2)：139-140
[48]张静,李庚山,李国草,等.兔阿霉素心衰模型的建立[J].心脏杂志,2004,16(5)：437-439
[49]Singal PK, Panagia V.Direct effects of adriamycin on the rat heart sarcolemma [J].Res commun Chem Pathol Pharmacol,1984,43 (1):67-77
[50]Torii M, Ito H, Suzuki T.Lipid peroxidation and myocardial vulnerability in hypertrophied SHR myocardium [J].Exp Mol Pathol,1992,57(1):29-38
[51]张小丽.大蒜素对阿霉素性心衰大鼠心功能的保护作用及其线粒体机制[J].药学进展,2010,34(1)：30-35
[52]黄先玫,康曼丽.阿霉素对实验兔心功能及心肌细胞内游离钙浓度的影响[J].浙江医学,2000,22(7)：402-404
[53]Polovlkova OG, Makeeva OA, Lezhnev AA, et al.Expression profile of calcineurin pathway genes in myocardium tissues in relation to ischemic heart remodeling in humans [J].Mol Biol (Mosk),2013,47(3):433-440.
[54]Lee TM, Lin MS, Chang NC. Effect of ATP-sensitive potassium channel agonists on ventricular remodeling in healed rat infarcts[J]. Am Coll Cardiol,2008, 51(13):1309-1318.
[55]葛均波,徐永健.内科学[M].北京：人民卫生出版社,2013：166
[56]Polovlkova OG, Makeeva OA, Lezhnev AA, et al.Expression profile of calcineurin pathway genes in myocardium tissues in relation to ischemic heart remodeling in humans [J].Mol Biol (Mosk),2013,47(3):433-440.
[57]Tang M, Li J, Huang W, et al. Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts [J].Cardiovasc Res,2010,88(3):424-433
[58]Sanna B, Brandt E B, Kaiser R A, et al. Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo[J]. Proc Natl Acad Sci USA,2006,103(19):7327-7332.
[59]戴文建,王以光.心肌肥厚分子机制研究进展[J].心血管病学进展,2009,30(1)： 47.
[60]Panther F, Williams T, Ritter O.Inhibition of the calcineurin-NFAT signalling cascade in the treatment of heart failure [J].Recent Pat Cardiovasc Drug Discov, 2009,4(3):180-186.
[61]Wolska B M. Calcineurin and cardiac function:is more or less better for the heart[J]. Am J Physiol Heart Circ Physiol,2009,297(5):1576-1577.
[62]van Rooij E, Doevendans PA, Crijns HJ, et al.MCIPl overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction [J].Cirs Res,2004,94:18-26
[63]Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy[J]. Biochem Biophys Res Commun,2004,322 (4): 1178-1191.
[64]Hu ST, Shen YF, Liu GS, et al.Altered intracellular Ca2+regulation in chronic rat heart failure [J] J Physiol Sci,2010,60(2):85-94
[65]崔国明,东燕,赵勇,等.钙调神经磷酸酶表达与心脏重构的关系[J].中华实用诊断与治疗杂志,2011,25(8)：758-762
[66]Diedriehs H, Hagemeister J, Chi M, et al. Activation of the calcineurin/NFAT signalling cascade starts early in human hypertrophic myocardium [J]. J Int Med Res,2007,35(6):803-818
[67]Lu M, Wang H, Wang J,et al.Astragaloside IV Protects against Cardiac Hypertrophy via Inhibiting the Ca2+/CaN Signaling Pathway[J].Planta Med,2014, 80(1):63-69
[68]Berry JM,Le V, Rotter D,et al.Reversibility of adverse, calcineurin-dependent cardiac remodeling [J].Circ Res,2011,109(4):407-417
[69]Wang GJ, Yao YS, Wang HX, et al.Calcineurin contributed to tumor necrosis factor alpha-induced cardiomyocyte hypertrophy in rats [J].Zhongguo Ying Yong ShengLi Xue Za Zhi,2012,28(2):184-188.
[70]郭炳彦,韩瑞,石英辉,等.姜黄素对血管紧张素Ⅱ诱导新生大鼠心肌细胞肥大的保护作用[J].现代中西医结合杂志,2011,20(2)：147-149
[71]Pan ZW, Zhang Y, Mei DH,et al.Scutellarin exerts its anti-hypertrophic effects via suppressing the Ca2+-mediated calcineurin and CaMKII signaling pathways [J]. Naunyn Schmiedebergs Arch Pharmacol,2010,381(2):137-145.
[72]熊娟,潘勇军,郭桂香,等.川芎嗪对肥大心肌细胞中钙调神经磷酸酶信号转导通路的干预作用[J].医药导报,2009,28(10)：1265-1268
[73]Moey M, Gan XT, Huang CX, et al.Ginseng reverses established cardiomyocyte hypertrophy and postmyocardial infarction-induced hypertrophy and heart failure [J].Circ Heart Fail,2012,5(4):504-514.
[74]Guo J, Gan XT, Haist JV, et al.Ginseng inhibits cardiomyocyte hypertrophy and heart failure via NHE-1 inhibition and attenuation of calcineurin activation [J].Circ Heart Fail,2011,4(1):79-88
[75]王照华,李永胜,杨乐,等.丹参酮对肥大心肌细胞中电生理特征和钙调神经磷酸酶活性的作用[J].现代中西医结合杂志,2011,20(32)：4060-4063
[76]童妍,党万太,苗维娜.参附汤对心阳虚型慢性心力衰竭钙调神经磷酸酶-活化T细胞核因子3信号转导通路的影响[J].中国实验方剂学杂志,2012,18(8)： 199-201
[77]党万太,苗维娜,杨晓放,等.基于钙调磷酸酶-活化T细胞核因子3信 号转导通路探究四逆汤治疗心力衰竭的分子机制[J].中国实验方剂学杂志,2011,17(22)：201-204
[78]郭志华,李雅,毛以林,等.益心泰治疗慢性心力衰竭60例临床观察[J].中成药,2008,30(3)：323-325
[79]郭志华,范红辉,李雅,等.益心泰治疗气虚血瘀水停型慢性心力衰竭[J].中西医结合心脑血管病杂志,2009,7(1)：5-6
[80]Meng R, Pei Z, Zhang A, et al. AMPK activation enhances PPARalpha activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway [J] Arch Biochem Biophys,2011,511 (1-2):1-7
[81]Meng RS, Pei ZH, Yin R, et al. Adenosine monophosphate-activated protein kinase inhibits cardiac hypertrophy through reactivating peroxisome proliferator-activated receptor-alpha signaling pathway[J]. Eur J Pharmacol,2009, 620 (1-3):63-70.
[82]Shi J, Zhang YW, Yang Y, et al.ROCKl plays an essential role in the transition from cardiac hypertrophy to failure in mice [J] J Mol Cell Cardiol,2010, 49(5):819-828.
[1]Gaddam KK, Verma A, Thompson M, et al. Hypertension and cardiac failure in its various forms [J].Med Clin North Am,2009,93(3):665-680
[2]Schannwell CM, Hennersdorf MG, Strauer BE. Hypertension and cardiac failure [J].Internist (Berl),2007,48(9):909-920
[3]Bamani GV,Uber PA, Mehra MR.Chronic heart failure:contemporary diagaosis and management[J].Mayo Clin Prec,2010,85(2):180-195.
[4]颜德馨.跟名师学临床系列丛书：颜德馨[M].第2版.北京：中国医药科技出版社,2010：3-4.
[5]杨宝元,任秀英,杨阳,等.慢性收缩性心力衰竭与中医气虚血瘀病机相关性研究[J].中西医结合心脑血管病杂志,2011,9(10)：1153-1154
[6]姜平,李冰,刘艳,等.益气养阴和化瘀利水中药治疗糖尿病合并冠心病慢性心功不全老年患者32例[J].中国中西医结合急救杂志,2011,18(3)：178.
[7]谢兴辉.温阳益气活血利水法配常规西药治疗慢性心力衰竭75例[J].陕西中医,2009,30(6)：646
[8]林凯旋,缪灿铭,麦美琪,等.益气活血利水法治疗慢性心力衰竭的临床研究[J].光明中医,2009,24(11)：2132-2133
[9]郭志华,范红辉,李雅,等.益心泰治疗气虚血瘀水停型慢性心力衰竭[J].中西医结合心脑血管病杂志,2009,7(1)：5-6
[10]刘会红,万秀英,李红英,等.益气活血利水法治疗慢性充血性心力衰竭148例[J].北京中医药,2011,30(10)：733-736
[11]王兴.益气活血利水方治疗气虚血瘀型慢性心力衰竭60例[J].中国中医药现代远程教育,2011,9(9)：30-31
[12]陈英全,谢绍洽.苯那普利对慢性心衰患者心功能-内分泌-细胞因子的影响[J].中国现代医药杂志,2010,12(5)：26-29
[13]伍鹏龙,魏盟,朱伟.Scrf信号通路及在心力衰竭病理生理中的作用[J]国际心血管病杂志,2013,40(1)：6-8,15
[14]朱德胜,冯耀光.心力衰竭时神经内分泌改变[J].中国现代医生,2010,32(10)：130-131.
[15]郎中云,方显明.安心颗粒对慢性心衰大鼠细胞因子和心肌重构的影响[J].时珍国医国药,2011,22(7)：1584-1585
[16]方显明,刘神州,吴功恩,等.安心颗粒对心力衰竭大鼠JAK1-STAT3信号通路的影响.新中医,2011,43(7)：126-129
[17]李莹,马会军.慢性心力衰竭患者血尿酸与心功能的关系[J].当代医学, 2013,19(25) ：41
[18]温继梨,崔晓迎,陈凤英.N端脑钠肽、脑钠肽及ST2与心力衰竭患者严重程度相关性分析[J].中国医药导报,2013,10(2)：76-77,80
[19]谭海彦,朱莉,周萍,等.谈益气活血法对慢性心衰的临床观察及对NT— proBNP的影响[J].求医问药,2011,9(10)：300-301
[20]徐辉.温阳益气行瘀利水对慢性心衰LVEF及血脑利钠肽影响[J].中医临床研究,2011,3(15)：5-7
[21]林凯旋,陈翊.益气活血法改善心衰患者左室射血分数及脑钠肽的临床研究[J].光明中医,2010,25(9)：1614-1615
[22]李玲,黄云辉.益气活血利水方对慢性心力衰竭BNP水平影响的临床研究[J].中国社区医师,2009,11(20)：166
[23]刘茜,周华,戎靖枫.温补肾阳方对心肌梗死后心力衰竭大鼠血流动力学及血清肌钙蛋白Ⅰ和脑钠肽含量的影响[J].天津中医药,2013,30(3)：164-167
[24]王建湘,谭元生,邓满霞.温阳益气、活血利水法对冠脉结扎心肌梗死后心衰大鼠NT-proBNP(?)影响[J].中西医结合心脑血管病杂志,2012,10(3)：325-326
[25]Akkus MN, Polat G, Yurtdas M, et al. Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission[J]. Int Heart J,2009, 50(1):33-45
[26]Fichtlscherer S, RosenbererG, Dirk H, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease[J]. Circulation,2000,102:1000-1006.
[27]刘芳.NT-proBNP, HCY, hs-CRP检测对慢性心衰的诊断价值[J].中国实用医药,2013,8(28)：105-106
[28]翁锦龙.黄芪丹参饮对气虚血瘀慢性心力衰竭患者NT-proBNP. CRP水平及心功能的影响[J].中国医药科学,2011,1(22)：17-19
[29]谢培怡,李晓玲,许琳,等.益气活血利水法对心力衰竭患者脑钠肽及超敏C-反应蛋白的影响[J].中国中西医结合急救杂志,2011,18(5)：280-283
[30]Cowburn PJ,Cleland JGF. Endothelin antagonists for chronic heart failure:do they have a role[J]? Eur Heart J,2001,22 (19):1772-1784
[31]Ohmae M.Endothelin-1 levels in chronic congestive heart failure[J].Wien Klin Wochenschr,2011,123(23-24):714-717
[32]Wang L, Shi J, Zhang Y.Influences of simvastatin on vascular endothelial function of patients with coronary heart disease complicated with congestive heart failure[J].Eur Rev Med Pharmacol Sci,2013,17(12):1590-1593.
[33]Hurli mann D, Enseleit F,Noll G, et al. Endothelin antagonists and heart failure[J]. Curr Hypertens Reports,2002,4 (1):85-92.
[34]McMurray JJV.Heart failure in 10 years time:Focus on pharmacological treatment[J].Heart,2002,88(supp 1Ⅱ):1402-1146
[35]黄平东,罗懿明,刘煜德,等.益气温阳活血利水药对心梗后心衰ET-1、TNF-A. AngⅡ的影响[J].四川中医,2009,27(11)：37-40
[36]王东,刘江,王晓峰.芪红汤治疗慢性心力衰竭气虚血瘀型疗效及对血浆内皮素、脑钠肽的影响[J].新疆医科大学学报,2011,34(4)：379-382
[37]Nishilkimi T, Maeda N, Mmsuoka H. The role of natriuretic peptides in cardioprotection[J]. Cardiovasc Res,2006,69(2):318-328
[38]De Bold AJ, De Bold ML. Determinants of natriuretic peptide production by the heart:basic and clinical implication[J]. Investig Med,2005,53(7):371-377
[39]Tsuneyoshi H, Nishina T, Nomoto T, et al. Atrial natriuretic peptide helps prevent late remodeling after left ventriclar aneurysmrepair[J]. Circulation,2004, 110(11Supp11):174-179
[40]亢顺阳,田大利.血浆心钠素和脑钠素在慢些心力衰竭患者中的水平改变意义分析[J].中国现代药物应用,2013,7(21)：47-48
[41]王永霞,任红杰,朱明军,等.参附益心颗粒对慢性心力衰竭大鼠血清心钠素、脑钠素的影响[J].中国实验方剂学杂志,2011,17(4)：118-120
[42]Xu J, Lu XW, Huang Y, et al. Synergism of simvastatin with losartan prevents angiotensin Ⅱ-induced cardiomyocyte apoptosisin vitro[J].J Pharm Pharmacol, 2009,61 (4):503
[43]Alves AJ, Eynon N, Oliveira J,et al. RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications[J].World J Cardiol,2010,2(7): 187-197.
[44]刘淑荣,张晓华,于清华,等.益气活血利水法治疗心力衰竭大鼠的作用机制[J].中国老年性杂志,2011,31(21)：4191-4193
[45]宫广舵,陈远平,李瑜欣,等.养心通脉颗粒II方对气虚血瘀型心衰大鼠血清AngⅡ, IL-6, TNF-a水平的影响[J].广西中医学院学报,2010,13(4)：1-3
[46]Wang GJ, Wang HX, Yao YS, et al.The role of Ca2+/calmodulin-dependent protein kinase Ⅱ and calcineurin in TNF-a-induced myocardial hypertrophy[J].Braz J Med Biol Res,2012,45(11):1045-1051.
[47]Wang GJ, Yao YS, Wang HX, et al.Calcineurin contributed to tumor necrosis factor alpha-induced cardiomyocyte hypertrophy in rats[J].Zhongguo Ying Yong Sheng Li Xue Za Zhi,2012,28(2):184-188.
[48]Amir O, Rogowski O, David M, et al.Circulating interleukin-10:association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha[J]. Isr Med Assoc J,2010,12(3):158-162
[49]Sven W, Micheala S, Kerstin S, et al. Interleukin-6 induced oxidative stress and endothelial dysfunction by overexpression of the angiotensin 2 type 1 receptor[J]. Cir
Res,2004,94:534-541. [50] Christian M,Kirsten LK, Andreas C, et al. Inflammation and long term mortality in acute congestive heart failure[J]. Am Heart J,2006,151(4):845-850.
[51]Kinugawa T, Kato M, Yamamoto K, et al.Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure[J].Int Heart J.2012,53(3):182-186
[52]赵淑明,郭秋红,张志良,等.葶苈生脉方对慢性心衰大鼠血清肿瘤坏死因子-、白细胞介素-6及心肌胶原的影响[J].时珍国医国药,2010,21(1)：153α-154
[53]王扬,杜立建,陈希芬.益气活血汤对慢性充血性心力衰竭患者抗炎细胞因子及心功能的影响[J].河北中医,2009,31(9)：1292-1294
[54]礼海,张艳,马金.益气活血复方联合运动疗法对慢性心衰大鼠心肌组织 MMP-1及Ⅲ型胶原表达的影响[J].中国中西医结合杂志,2011,31(7)：955-960
[55]黄东平,刘煜德,黄衍寿.益气温阳活血利水药对心梗后心衰大鼠基质金属蛋白酶及心室重塑的影响[J].中药新药与临床药理,2010,21(6)：608-611
[56]马金,张艳.益气活血复方对慢性心衰大鼠心肌重构影响的实验研究[J].时珍国医国药,2011,22(6)：1361-1362
[57]Moshal KS, Rodriguez WE, Sen U, et al. Targeted deletion of MMMP-9 attenuates myocardial contractile dysfunction in heart failure[J]. Physiol Res,2008, 57(3):379-384
[58]刘晓蕾,张艳,礼海.益气活血中药对心力衰竭大鼠MMP-K TIMP-1影响的实验研究[J].天津中医药,2011,28(6)：503-505
[59]Polovlkova OG, Makeeva OA, Lezhnev AA, et al.Expression profile of calcineurin pathway genes in myocardium tissues in relation to ischemic heart remodeling in humans[J].Mol Biol (Mosk),2013,47(3):433-440.
[60]Tang M, Li J, Huang W, et al. Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts[J].Cardiovasc Res,2010,88(3):424-433
[61]Panther F, Williams T, Ritter O. Inhibition of the calcineurin-NFAT3 signalling cascade in the treatment of heart failure [J]. Recent Pat Cardiovasc Drug Discov, 2009,4(3):180-186.
[62]Lu M, Wang H, Wang J,et al.Astragaloside IV Protects against Cardiac Hypertrophy via Inhibiting the Ca2+/CaN Signaling Pathway[J].Planta Med,2014, 80(1):63-69
[63]Wilkins BJ,Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy[J]. Biochem Biophys Res Commun,2004,322 (4):1178-1191.
[64]杨冬花,卞震炯,付蓉.益气温阳活血方对慢性心衰大鼠心室重构基因表达谱的影响[J].陕西中医,2009,30(6)：740-742
[65]郭志华,吴刚强,申思,等.益心泰对慢性心力衰竭大鼠心肌重构钙调神经磷酸酶信号通道的影响[J].中国中医急症杂志,2013,22(1)：17-19
[66]朱茜,贾如意,高佩增.冠心病心力衰竭患者血清NF-κB水平变化及 意义[J].山东医药,2010,50(23)：7-9
[67]Sudhiranjan Gupta,David Young, Ratan, et al. Prevention of Cardiac Hypertrophy and Heart Failure by Silencing of NF-κB[J]. J M01 Biol,2008,375(3): 637
[68]杨志霞,林谦,农一兵,等.黄芪多糖联合丹参酮对心衰大鼠心肌NF-κB通路过度激活的影响[J].北京中医药大学学报,2011,34(9)：609-612
[69]柯元南.心力衰竭的血流动力学[J].中国前沿医学杂志,2010,2(1)：13-15
[70]Chung I, Choudhury A, Lip GY. Platelet activation in acute, decompensated congestive heart failure [J]. Thromb Res,2007,120(5):709-713.
[71]Kandis H, Ozhan H, Ordu S, et al. The prognostic value of mean platelet volume in decompensated heart failure [J]. Emerg Med J,2011,28(7):575-578.
[72]Chung I, Choudhury A, Patel J, et al. Soluble, platelet-bound, and total p-selectin as indices of platelet activation in congestive heart failure[J].Ann Med,2009,41(1): 45-51.
[73]沈荣春,王峰,徐耀忠,等.4项血小板参数检测在慢性心力衰竭诊疗中临床价值[J].交通医学,2013,27(3)：263-265
[74]王中全,张洋, 陈曦,等.hs-CRP和血小板参数与心衰患者病情严重程度的关系[J].中国老年学杂志,2013,33(14)：3320-3322
[75]沈淑静,冼绍,黄衍寿,等.益气温阳活血利水中药对心力衰竭兔的血流动力学影响和配伍研究[J].中国实验方剂学杂志,2013,19(5)：195-199
[76]张艳,海丽,宋婷婷,等.益气活血复方对慢性心衰大鼠血小板活化影响的实验研究[J].世界中西医结合杂志,2008,3(4)：198-200
[77]李华.中药抗心衰合剂治疗气虚血瘀阳虚水泛型充血性心力衰竭临床研究[J].中医中药,2012,9(3)：104-105
[78]刘强,李萌,钟志国,等.益气活血利水汤治疗冠心病慢些心力衰竭44例[J].山东中医杂志,2009,28(8)：533-534
[79]安冬青,王晓峰,陈继红,等.芪红颗粒结合康复治疗气虚血瘀型心力衰竭的临床观察.第十次中国中西医结合学会心血管病暨第五次江西省中西医结合学
会心血管病学术大会论文集：243-246
[80]郑军,刘金玲.中西医结合治疗气虚血瘀型慢性充血性心力衰竭37例[J].西部中医药,2011,24(12)：62-64